• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病的共病和衰弱问题思考

Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases.

机构信息

Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Academic Unit for Ageing and Stroke Research, University of Leeds, Bradford Institute for Health Research, Bradford, UK.

出版信息

J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii46-ii54. doi: 10.1093/ecco-jcc/jjae067.

DOI:10.1093/ecco-jcc/jjae067
PMID:39475079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11523040/
Abstract

There are growing numbers of older people with inflammatory bowel diseases [IBD]. These older patients are more likely to have other comorbidities and polypharmacy, which can make recognizing and treating IBD complex. Frailty is a newer concept in the IBD field, and we are beginning to recognize the importance of this as a marker of biological age and its association with risk of adverse IBD-related outcomes. In this review article we aim to provide practical insight into the specific challenges facing older patients and their clinicians at each stage of the patient journey. We also discuss the latest understanding of the impact of frailty for these patients with IBD and highlight areas for future research.

摘要

患有炎症性肠病(IBD)的老年人数量正在增加。这些老年患者更有可能患有其他合并症和多种药物治疗,这使得识别和治疗 IBD 变得复杂。虚弱是 IBD 领域的一个新概念,我们开始认识到它作为生物年龄的标志物及其与不良 IBD 相关结局风险的关联的重要性。在这篇综述文章中,我们旨在为老年患者及其临床医生在患者旅程的每个阶段所面临的具体挑战提供实用的见解。我们还讨论了最新的关于虚弱对这些 IBD 患者的影响的理解,并强调了未来研究的领域。

相似文献

1
Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases.炎症性肠病的共病和衰弱问题思考
J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii46-ii54. doi: 10.1093/ecco-jcc/jjae067.
2
Frailty: An Underappreciated Risk Factor for IBD Complications.衰弱:IBD 并发症的一个被低估的风险因素。
Curr Gastroenterol Rep. 2024 Dec;26(12):315-322. doi: 10.1007/s11894-024-00945-5. Epub 2024 Sep 5.
3
Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study.炎症性肠病患者在三级保健中心的共病情况:一项回顾性研究。
BMC Gastroenterol. 2022 Nov 26;22(1):487. doi: 10.1186/s12876-022-02578-2.
4
Challenges in the management of older patients with inflammatory rheumatic diseases.老年炎症性风湿病患者管理面临的挑战。
Nat Rev Rheumatol. 2022 Jun;18(6):326-334. doi: 10.1038/s41584-022-00768-6. Epub 2022 Mar 21.
5
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.新发炎症性肠病老年患者中衰弱的患病率及其影响:一项全国性队列研究
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2358-2365.e11. doi: 10.1016/j.cgh.2022.01.001. Epub 2022 Jan 6.
6
An overview of multimorbidity and polypharmacy in older people living with HIV.老年人中合并多种疾病和多种药物治疗的概述。
Geriatr Gerontol Int. 2024 Mar;24 Suppl 1:49-59. doi: 10.1111/ggi.14717. Epub 2023 Nov 8.
7
Frailty in inflammatory bowel disease: analysis of the National Inpatient Sample 2015-2019.炎症性肠病患者的虚弱状况:2015-2019 年国家住院患者样本分析。
Colorectal Dis. 2024 May;26(5):958-967. doi: 10.1111/codi.16967. Epub 2024 Apr 4.
8
Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis.炎症性肠病患者衰弱的患病率及其与临床结局的关系:系统评价和荟萃分析。
BMC Gastroenterol. 2022 Dec 22;22(1):534. doi: 10.1186/s12876-022-02620-3.
9
Aging and IBD: A New Challenge for Clinicians and Researchers.衰老与炎症性肠病:临床医生和研究人员面临的新挑战。
Inflamm Bowel Dis. 2022 Jan 5;28(1):126-132. doi: 10.1093/ibd/izab039.
10
New horizons in multimorbidity in older adults.老年人多病共存的新视野。
Age Ageing. 2017 Nov 1;46(6):882-888. doi: 10.1093/ageing/afx150.

引用本文的文献

1
IBD Across the Ages-A Journey Together.穿越岁月的炎症性肠病——共同之旅
J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii1-ii2. doi: 10.1093/ecco-jcc/jjae118.

本文引用的文献

1
Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study.维得利珠单抗治疗炎性肠病患者时不会增加艰难梭菌感染风险:一项回顾性队列研究
Saudi Pharm J. 2023 Sep;31(9):101736. doi: 10.1016/j.jsps.2023.101736. Epub 2023 Aug 5.
2
Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases.炎症性肠病患者虚弱表型的可逆性
J Clin Med. 2023 Apr 3;12(7):2658. doi: 10.3390/jcm12072658.
3
Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study.炎症性肠病的住院率随时间呈下降趋势:一项基于人群的队列研究。
Inflamm Bowel Dis. 2023 Oct 3;29(10):1536-1545. doi: 10.1093/ibd/izad020.
4
Comparative effectiveness of non-pharmacological interventions for frailty: a systematic review and network meta-analysis.非药物干预对衰弱的比较效果:一项系统评价和网状Meta分析
Age Ageing. 2023 Feb 1;52(2). doi: 10.1093/ageing/afad004.
5
Conventional Frailty Index Does Not Predict Risk of Postoperative Complications in Patients With IBD: A Multicenter Cohort Study.常规虚弱指数不能预测 IBD 患者术后并发症的风险:一项多中心队列研究。
Dis Colon Rectum. 2023 Aug 1;66(8):1085-1094. doi: 10.1097/DCR.0000000000002524. Epub 2022 Dec 15.
6
Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis.炎症性肠病患者衰弱的患病率及其与临床结局的关系:系统评价和荟萃分析。
BMC Gastroenterol. 2022 Dec 22;22(1):534. doi: 10.1186/s12876-022-02620-3.
7
Frail Phenotype in Patients With Inflammatory Bowel Disease.炎症性肠病患者的虚弱表型。
Inflamm Bowel Dis. 2023 Oct 3;29(10):1555-1562. doi: 10.1093/ibd/izac242.
8
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.评估溃疡性结肠炎临床项目中按年龄分层的托法替布的安全性和疗效。
Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084.
9
Is it time to include older adults in inflammatory bowel disease trials? A call for action.是否到了将老年人纳入炎症性肠病临床试验的时候了?呼吁采取行动。
Lancet Healthy Longev. 2022 May;3(5):e356-e366. doi: 10.1016/S2666-7568(22)00060-5. Epub 2022 May 4.
10
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.乌司奴单抗在老年克罗恩病患者中的有效性和安全性:来自ENEIDA注册研究的真实世界证据
J Crohns Colitis. 2023 Jan 27;17(1):83-91. doi: 10.1093/ecco-jcc/jjac108.